Human platelet activation by Escherichia coli: roles for FcγRIIA and integrin αIIbβ3 by Watson, Steve P.. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=iplt20
Download by: [University of Hull] Date: 16 May 2016, At: 05:40
Platelets
ISSN: 0953-7104 (Print) 1369-1635 (Online) Journal homepage: http://www.tandfonline.com/loi/iplt20
Human platelet activation by Escherichia coli: roles
for FcγRIIA and integrin αIIbβ3
Callum N. Watson, Steven W. Kerrigan, Dermot Cox, Ian R. Henderson, Steve
P. Watson & Mònica Arman
To cite this article: Callum N. Watson, Steven W. Kerrigan, Dermot Cox, Ian R. Henderson,
Steve P. Watson & Mònica Arman (2016): Human platelet activation by Escherichia coli: roles for
FcγRIIA and integrin αIIbβ3, Platelets, DOI: 10.3109/09537104.2016.1148129
To link to this article:  http://dx.doi.org/10.3109/09537104.2016.1148129
Published with license by Taylor & Francis.©
2016 Callum N. Watson, Steven W. Kerrigan,
Dermot Cox, Ian R. Henderson, Steve P.
Watson, & Mònica Arman
Published online: 30 Mar 2016.
Submit your article to this journal 
Article views: 85
View related articles 
View Crossmark data
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Abstract
Gram-negative Escherichia coli cause diseases such as sepsis and hemolytic uremic syndrome in
which thrombotic disorders can be found. Direct platelet–bacterium interactions might con-
tribute to some of these conditions; however, mechanisms of human platelet activation by E.
coli leading to thrombus formation are poorly understood. While the IgG receptor FcγRIIA has a
key role in platelet response to various Gram-positive species, its role in activation to Gram-
negative bacteria is poorly defined. This study aimed to investigate the molecular mechanisms
of human platelet activation by E. coli, including the potential role of FcγRIIA. Using light-
transmission aggregometry, measurements of ATP release and tyrosine-phosphorylation, we
investigated the ability of two E. coli clinical isolates to activate platelets in plasma, in the
presence or absence of specific receptors and signaling inhibitors. Aggregation assays with
washed platelets supplemented with IgGs were performed to evaluate the requirement of this
plasma component in activation. We found a critical role for the immune receptor FcγRIIA,
αIIbβ3, and Src and Syk tyrosine kinases in platelet activation in response to E. coli. IgG and
αIIbβ3 engagement was required for FcγRIIA activation. Moreover, feedback mediators adeno-
sine 5’-diphosphate (ADP) and thromboxane A2 (TxA2) were essential for platelet aggregation.
These findings suggest that human platelet responses to E. coli isolates are similar to those
induced by Gram-positive organisms. Our observations support the existence of a central
FcγRIIA-mediated pathway by which human platelets respond to both Gram-negative and
Gram-positive bacteria.
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Introduction
Platelets have been long known to be activated by bacteria [1]. This
is likely to contribute to a balanced immune response [2], but it is
also associated with pathological conditions such as infective endo-
carditis, atherothrombosis, and sepsis [3–5]. In the latter, dissemi-
nated microvascular thrombosis has a role in pathophysiology of
sepsis and might be mediated through direct platelet–bacterium
interactions. Recently, great emphasis has been placed on under-
standing the molecular mechanisms by which platelets are activated
by bacterial cells. Elucidation of such mechanisms would provide
opportunities to regulate them during infection. These mechanisms
are diverse and include activation by whole bacteria or their released
products [1, 6]. Despite multiple bacterial-strain specific molecular
interactions, human platelet FcγRIIA is required for activation by a
number of different Gram-positive species [7–15] and might con-
tribute to the thrombotic complications found in infective diseases
[15]. FcγRIIA is a low-affinity receptor for the constant region of
IgGs that recognizes IgG-coated bacteria or their products through
avidity. Upon ligand engagement, FcγRIIA signals through Src and
Syk tyrosine kinases via a dual YxxL sequence known as an immu-
noreceptor tyrosine-based activation motif (ITAM) that is present in
its cytoplasmic tail [16].
Gram-negative E. coli are commensal bacteria of the human
and other mammalian gastrointestinal tracts. They rarely cause
disease, except in cases of damaged gastrointestinal barriers or
immunocompromised hosts. However, pathogenic strains of E.
coli can cause three general clinical syndromes: enteric/diarrheal
disease, urinary tract infections, and sepsis/meningitis [17]. In
the latter, E. coli strains are the most common Gram-negative
bacteria isolated from patients with bacteremia, sepsis, and
neonatal meningitis [17–20], causing a major clinical burden
and thousands of deaths per year. However, scarce information
is available on the molecular interactions between E. coli and
platelets [21].
The aim of this study was two-fold: to investigate human
platelet activation by whole E. coli clinical isolates, and to inves-
tigate if FcγRIIA mediates platelet activation.
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Materials and methods
Reagents
All reagents were from described sources [14]. Fibrinogen was
from Calbiochem (Merck Millipore, Nottingham, UK) and was
depleted of IgGs by incubation with protein A (rec-Protein
A-Sepharose 4B Conjugate, Life Technologies [Paisley, UK]).
Bacterial culture and preparation
E. coli strains, CFT073 (isolated from a patient with acute pye-
lonephritis and bacteremia [22]) and RS218 (isolated from a case
of neonatal meningitis [23]), were cultured aerobically at 37°C
overnight in an LB broth. Bacteria were washed and adjusted in
PBS to an optical density (OD) of 1.6 at a wavelength of 600 nm.
Bacteria were used at a 10-fold dilution in aggregation assays
unless otherwise indicated.
Assays of platelet function
Platelet preparation from healthy volunteers was performed as
previously described [14]. The study design was approved by
the relevant ethics committee (ERN_11-0175). Platelet aggrega-
tion was assessed by light transmission in a PAP-8 aggregometer
for up to 30 min. Time-matched controls were run alongside.
Stimulation by cross-linking of FcγRIIA was performed by pre-
incubation of platelets for 3 min with mAb IV.3 (4 μg/mL)
followed by anti-mouse IgG F(ab’)2 (30 μg/mL). When indicated,
concentrations of both mAb IV.3 and anti-mouse IgG F(ab’)2
were doubled or reduced to half. ATP release was assessed at
the end of the recording using a luciferin–luciferase based assay
[9]. Eptifibatide (9 μM), dasatinib (4 μM), and PRT-060318 (10
μM) were used at supramaximal concentrations.
Cell lysates and protein phosphorylation studies were per-
formed as previously published [14].
Statistical analysis
Statistical analysis was performed using GraphPad (Prism). Data
are presented as mean ± standard deviation (SD), and compar-
isons between mean values were performed using Student’s t-test
or ANOVA when multiple samples were compared. p < 0.05
(two-tailed) was considered to be significant.
Results and discussion
E. coli bacteria stimulate αIIbβ3-mediated platelet
aggregation via FcγRIIA and Src and Syk tyrosine kinases
Previous studies have shown a characteristic pattern of plate-
let activation by Gram-positive bacteria, i.e. they induce “all-
or-nothing” aggregation of platelets following a lag time that
decreases with increasing concentrations of bacteria [14]. We
hypothesized that Gram-negative organisms could trigger pla-
telet aggregation in a similar manner. To test this, we inves-
tigated two blood-borne isolates of E. coli, CFT073, which
was isolated from a patient with urinary tract infection and
bacteremia, and RS218, which was isolated from a child with
meningitis. We found that both strains induced “all-or-noth-
ing” platelet aggregation in plasma after a lag phase (Figure 1
A.i and B.i). In contrast, as exemplified in Figure 1C for
cross-linking of mAb IV.3 to cluster FcγRIIA, most platelet
agonists cause rapid activation, which can give rise to partial
aggregation when low concentrations of agonist are used. This
suggests that bacteria have a unique positive feedback
mechanism that gives rise to an “all-or-nothing” response.
The rest of the study was performed with the intermediate
bacterial concentration; e.g. bacterial suspensions at OD600nm 1.6
were used at a 10-fold dilution in aggregation assays. Under these
experimental conditions and performing the reactions in the pre-
sence of plasma, both strains induced platelet aggregation in six out
of seven donors tested. For E. coli CFT073, the lag time for the
onset of aggregation varied from 130 to 330 sec (mean ± SD: 200
sec ± 69, n = 6) (Figure 1A.ii). E. coli RS218 induced aggregation
with lag times ranging from 120 to 270 sec (mean ± SD: 180 sec ±
58, n = 6) (Figure 1B.ii).
As shown in Figure 2A and B, platelet aggregation to E. coli
CFT073 and RS218 was blocked in the presence of the αIIbβ3
Figure 1. E. coli clinical isolates stimulating platelet aggregation in
plasma. (A) Effect of E. coli CFT073 concentration on the lag time for
the onset of platelet aggregation. (A.i) Bacterial suspensions at OD600nm
1.6 were used at different dilutions in platelet aggregation assays as
indicated. Platelet-rich plasma (PRP) was 80% of the final volume and
was kept constant in all reactions. (A.ii) Lag time for the onset of
aggregation was measured in platelets from seven different donors using
a 10-fold dilution of the bacterial suspension. Aggregation was observed
in six out of seven donors, and lag times are indicated. Experiments were
performed on different days (mean ± SD, n = 6). (B) Effect of E. coli
RS218 concentration on the lag time for the onset of platelet aggregation.
(B.i) Assays were performed as indicated in A.i. for E. coli RS218. (B.ii)
Lag time for the onset of aggregation was measured as explained in A.ii.
Aggregation was observed in six out of seven donors, and lag times are
indicated. Experiments were performed on different days (mean ± SD, n
= 6). (C) Effect of crosslinked mAb IV.3 concentration on platelet
aggregation. In order to crosslink the FcγRIIA receptor, platelets were
pre-incubated for 3 min with 2, 4 or 6 μg/mL mAb IV.3 followed by
addition of 15, 30, or 45 μg/mL anti-mouse IgG F(ab’)2, respectively.
Platelet-rich plasma (PRP) was 80% of the final volume and was kept
constant in all reactions.
2 C. N. Watson et al. Platelets, Early Online: 1–6
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antagonist eptifibatide, which confirmed that the change in light
transmission was due to αIIbβ3-mediated platelet–platelet binding
rather than passive agglutination.
To analyze whether FcγRIIA and its signaling pathway com-
ponents, Src and Syk tyrosine kinases, have a role in E. coli
induced platelet aggregation, specific inhibitors were employed.
Aggregation induced by E. coli CFT073 or RS218 strains was
abolished when platelets were pre-incubated with either mAb IV.3
(FcγRIIA inhibitor, Figure 2A and 2B), dasatinib (Src inhibitor,
Figure 2C and 2D), or PRT-060318 (Syk inhibitor, Figure 2C and
2D) in the presence of plasma.
Platelet activation by E. coli requires the interplay between
αIIbβ3 and FcγRIIA
A key role for FcγRIIA in platelet activation by E. coli is further
supported by the observation that dense granule secretion was
inhibited by mAb IV.3 (Figure 3A.i and A.ii) and that FcγRIIA
became phosphorylated in response to both E. coli CFT073 and
RS218 strains (Figure 3B). Furthermore, while washed platelets
were not able to support bacteria-mediated aggregation, aggrega-
tion to E. coli RS218 was restored in the presence of human IgGs
(e.g. pooled human IgGs purified from healthy donors) alone or
with fibrinogen (Figure 3C.ii). Simultaneous addition of human
IgGs and fibrinogen was necessary for E. coli CFT073 to induce
aggregation in washed platelets (Figure 3C.i). These observations
suggest that the initiating event in activation is engagement of
FcγRIIA by plasma IgG bound to bacteria.
Research on Gram-positive bacteria has shown that platelet
activation is often the result of multiple bacterium–platelet mole-
cular interactions. These include the combination of bacterial strain-
specific molecular interactions and shared IgG-FcγRIIA mediated
signaling events [6, 14]. Among the former, strain-specific
streptococci and staphylococci proteins are found that bind directly
or indirectly (e.g. via fibrinogen) to platelet surface receptors such
as αIIbβ3 or GPIb [6, 24]. Our results suggest that the mechanisms
of platelet activation by E. coli might also have a strain-dependent
component. However, future work is necessary to characterize the
exact molecular interactions between platelets and these two E. coli
strains, including the identification of potential bacterial compo-
nents binding (directly or indirectly) to platelet surface receptors.
Previous studies demonstrated an unexpected role for αIIbβ3
in controlling platelet dense granule secretion and FcγRIIA phos-
phorylation in response to a wide range of Gram-positive bacteria
[13, 14]. We analyzed whether the same pattern of regulation
could take place for E. coli. Indeed, E. coli CFT073 and RS218-
induced dense granule secretion was inhibited by eptifibatide
(Figure 3A.i and 3A.ii) demonstrating that secretion is dependent
on αIIbβ3 engagement. In contrast, secretion induced by cross-
linked mAb IV.3 was not decreased by eptifibatide (Figure 3A.
iii). Moreover, bacteria-induced tyrosine phosphorylation of
FcγRIIA was also dependent on αIIbβ3 engagement as observed
by the inhibition of phosphorylation in the presence of eptifiba-
tide (Figure 3B).
The inability to detect secretion and FcγRIIA tyrosine phos-
phorylation in the absence of αIIbβ3 engagement might reflect
the weak nature of the pathway initiated after FcγRIIA engage-
ment by IgG-coated bacteria in the absence of feedback signals.
The mechanism by which initial αIIbβ3 engagement takes place
is, however, unclear. Strain-specific events mediating αIIbβ3 acti-
vation are thought to exist for Gram-positive bacteria. For most
cases, it is likely that αIIbβ3 inside-out activation is achieved by
FcγRIIA signaling, as well as by signaling from other strain-
specific bacterial ligand–platelet receptor pairs. However, some
bacteria such as Streptococcus gordonii DL1 and Staphylococcus
aureus Newman can bind directly or indirectly (e.g. via
Figure 2. E. coli-induced platelet aggregation in plasma depends on FcγRIIA and Src and Syk tyrosine kinases. (A) Effect of αIIbβ3 antagonist,
eptifibatide, and anti-FcγRIIA mAb IV.3 on E. coli CFT073-induced platelet aggregation. PRP was incubated for 2 min with eptifibatide (9 μM) or 10
min with mAb IV.3 (10 μg/mL) or vehicle prior to addition of bacteria, and platelet aggregation was monitored by light transmission aggregometry.
The results on the right-hand side graph are shown as mean ± SD of five independent experiments; *p < 0.05. One representative experiment is shown
on the left. (B) Effect of αIIbβ3 antagonist, eptifibatide, and anti-FcγRIIA mAb IV.3 on E. coli RS218-induced platelet aggregation. The same
experimental conditions as in Figure 2A were used for E. coli RS218. The results on the right-hand side graph are shown as mean ± SD of four
independent experiments; *p < 0.05. One representative experiment is shown on the left. (C) Effect of the Src-tyrosine kinase inhibitor, dasatinib, and
the Syk-tyrosine kinase inhibitor, PRT-060318, in E. coli CFT073-induced platelet aggregation in plasma. PRP was incubated for 2 min with dasatinib
(4 μM) or PRT-060318 (10 μM) or vehicle prior to addition of bacteria, and platelet aggregation was monitored. The results on the right-hand side
graph are shown as mean ± SD of four independent experiments; *p < 0.05. One representative experiment is shown on the left. (D) Effect of the Src-
tyrosine kinase inhibitor, dasatinib, and the Syk-tyrosine kinase inhibitor, PRT-060318, in E. coli RS218-induced platelet aggregation in plasma. The
same experimental conditions as in Figure 2C were used for E. coli RS218. The results on the right-hand side graph are shown as mean ± SD of four
independent experiments; *p < 0.05. One representative experiment is shown on the left.
DOI: 10.3109/09537104.2016.1148129 FcγRIIA-mediated platelet activation by E. coli 3
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fibrinogen) to αIIbβ3, which could facilitate αIIbβ3 activation [1,
10, 25–27]. Further investigations are necessary to characterize
the mechanisms that lead to αIIbβ3 activation by E. coli CFT073
and RS218, including the identification of potential E. coli
ligands binding to αIIbβ3.
Platelet activation by E. coli is also dependent on secondary
mediators ADP and TxA2
Platelet activation is reinforced by secondary mediators, which
include release of stored ADP from dense granules and de novo
synthesis of TxA2. Positive feedback mechanisms driven by sec-
ondary mediators are normally required for full and/or sustained
platelet aggregation to low concentrations of agonists. This can be
seen in platelets stimulated with an intermediate concentration of
thrombin-related peptide (TRAP). Pre-treatment of platelets with
the ADP-receptor P2Y12 antagonist, Cangrelor, and/or with
cyclooxygenase inhibitor, indomethacin, did not affect the initial
TRAP-induced aggregation but was followed by slow deaggrega-
tion that was not seen in controls (Figure 4C).
In contrast, secondary mediators are key for platelet activation
to Staphylococcus and Streptococcus strains [14]. Here, inhibitors
were used to investigate a role for the two feedback agonists in E.
coli-induced platelet aggregation. Activation in response to E. coli
CFT073 and RS218 was completely abrogated in the presence of
either Cangrelor or indomethacin, or by the combination of both
(Fig 4A and 4B). Thus, platelet activation by E. coli bacteria is
also dependent on ADP and TxA2.
Altogether, these data suggest that the combination of
FcγRIIA activation upon recognition of IgG-coated bacteria plus
αIIbβ3 engagement (e.g. either through binding to bacteria or as a
result of inside-out platelet signaling events as discussed before)
results in a weak signal leading to release of ADP and TxA2. At
this stage, feedback mechanisms are key in order to achieve full
activation. Furthermore, ADP and TxA2 signal to neighboring
(bacteria-free) platelets and induce αIIbβ3 inside-out activation
and consequent platelet–platelet aggregation.
Interestingly, FcγRIIA has also been shown to function as an
adaptor protein amplifying αIIbβ3 signaling independent of extra-
cellular IgG engagement [28, 29]. This suggests that FcγRIIA and
αIIbβ3 could support both initial platelet–bacterium interaction and
subsequent platelet–platelet aggregation by means of cooperative
integrin/immunoreceptor tyrosine-based activation motif signaling.
In summary, in this study, we provide evidence that E. coli
induces activation of platelets through the same shared pathway
described for various Gram-positive Staphylococcus and
Streptococcus species [14]. This pathway involves IgG-dependent
FcγRIIA activation of Src and Syk kinases, and is reinforced by
αIIbβ3 engagement and secondary mediators. Despite the fact that
FcγRIIA-mediated aggregation was previously observed for
Gram-negative Helicobacter pylori [30] and Porphyromonas gin-
givalis [31], the signaling pathway and role of αIIbβ3 in activa-
tion has been only evaluated in few Gram-positive species [10,
13, 14]. The demonstration of a common mode of platelet activa-
tion to Gram-positive and Gram-negative species further identi-
fies FcγRIIA as a candidate receptor for prevention of bacteria-
mediated platelet activation in thrombosis and related disorders.
Figure 3. Platelet activation by E. coli requires the interplay between αIIbβ3 and FcγRIIA. (A) αIIbβ3 and FcγRIIA mediate E. coli induced platelet
secretion. Platelet-rich plasma was incubated for 2 min with eptifibatide (9 μM) or 10 min with mAb IV.3 (10 μg/mL) or vehicle prior to addition of
bacteria, and platelet aggregation was monitored by light transmission aggregometry. Reactions were also performed by crosslinking FcγRIIA receptor.
Platelets were pre-incubated for 3 min with 4 μg/mL monoclonal antibody (mAb) IV.3 followed by addition of 30 μg/mL anti-mouse IgG F(ab’)2.
Supernatants were collected at time of full aggregation, or a parallel time point in the case of inhibition. Supernatants were analyzed for ATP release by
luciferin–luciferase assay. ATP levels released by TRAP (100 μM) stimulated platelets were used to normalize data. The results are shown as mean ±
SD of five independent experiments for E. coli CFT073 and RS218 and three independent experiments for crosslinked mAb IV.3; *p < 0.05. (B) E. coli
induces tyrosine phosphorylation of FcγRIIA that is dependent on αIIbβ3. Aggregation reactions were performed in plasma in the presence or absence
of eptifibatide (9 μM) and cell lysates collected at time of full aggregation, or equivalent times in the case of eptifibatide-treated samples where
aggregation was inhibited. Immunoprecipitations for FcγRIIA were performed and tyrosine-phosphorylation detected by Western blot. Representative
results of three independent experiments are shown. (C) hIgGs reconstitute aggregation to E. coli in washed platelets. Aggregation reactions to E. coli
CFT073 and E. coli RS218 were performed in washed platelets in the presence or absence of IgG-depleted fibrinogen (1 mg/mL) and pooled human
IgGs from healthy donors (hIgG) (0.1 mg/mL). Three independent experiments were performed per strain using different platelet donors. One
representative experiment is shown for E. coli RS218. For E. coli CFT073, platelet aggregation was restored in two out of three platelet donors when
supplementing the reactions with fibrinogen plus hIgG, and one representative experiment is shown.
4 C. N. Watson et al. Platelets, Early Online: 1–6
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
ull
] a
t 0
5:4
0 1
6 M
ay
 20
16
 
We found that platelets from one out of seven donors did not
respond to either E. coli CFT073 or E. coli RS218. Donor varia-
tion in bacteria-induced platelet aggregation is common and has
been reported before [32, 33]. Future studies using a larger
number of donors will be required in order to evaluate the
potential effect of plasma IgG levels and FcγRIIA polymorphisms
and/or surface expression levels on human platelet aggregation in
response to E. coli. However, previous studies have not found a
clear correlation between donor response and the above para-
meters in the case of Gram-positive bacteria [32, 33] and, for
Streptococcus sanguinis, IgG levels can only partially account for
donor variability [33].
As previously mentioned, individual bacterial strains can med-
iate platelet–bacterium interactions by multiple receptor–ligand
pairs [1, 6], each one having a different contribution to the
adhesion and/or platelet activation steps. Although we have
found that FcγRIIA has a key role in human platelet activation
by E. coli CFT073 and RS218, other platelet receptors might be
simultaneously interacting with these strains, and this should be
investigated in future studies. Furthermore, the bacterial compo-
nents that are being targeted by IgGs-FcγRIIA remain to be
identified. Previous literature shows that E. coli secreted Shiga-
toxin, which is a virulent factor associated with hemolytic uremic
syndrome [34], induces platelet activation [35]. And this might
contribute to the formation of platelet thrombi in kidney glomer-
ular capillaries, small arterioles, and arteries [34]. Additionally,
human platelets bind lipopolysaccharide (LPS) from enterohe-
morrhagic E. coli via toll-like receptor (TLR) 4 and CD62, lead-
ing to cell activation [36]. TLR4-mediated platelet cytokine
secretion has been described in response to E. coli LPS [37].
While E. coli CFT073 and RS218 do not produce Shiga-toxin, a
role for E. coli CFT073 and RS218 cell wall LPS in platelet
activation cannot be discarded, either in relation to FcγRIIA-
mediated events (via IgG) or independently of the IgG receptor.
As a first approach to test the role of TLR4 in platelet activation
in response to our E. coli strains, we used an inhibitory anti-TLR4
antibody, HTA125, and found that it had no effect on platelet
aggregation, and did not prolong the lag time response to either E.
coli CFT073 or E. coli RS218 using two different donors (data
not provided). This suggests that TLR4 is not essential for platelet
activation by the bacterial strains tested. However, it is still
possible that E. coli LPS-IgG immune complexes are formed
that can engage platelet FcγRIIA directly. In any case, the exact
role of E. coli CFT073 and RS218 LPS and platelet TLR4 in
mediating platelet activation still needs to be deciphered.
Interestingly, one previous study showed that FcγRIIA was
required for platelet-mediated killing of IgG-opsonized E. coli
K12 [38]. This suggests that platelet activation by bacteria might
have different outcomes depending on the overall scenario: while
unbalanced thrombi formation might have detrimental effects in
cases such as HUS or sepsis, platelet activation by E. coli coated
with IgG found in sera from healthy individuals (i.e. such ones
used in this study) might contribute to host defense. Future
investigations are necessary to further decipher the molecular
interactions between E. coli and platelets, including potential
synergism between IgG-FcγRIIA and LPS-TLR mediated path-
ways, and their role in homeostasis or disease. Furthermore, in
view of the present study, care should be taken when using animal
models for the study of platelet function during E. coli infections
as FcγRIIA is not found in mice.
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